Beyond the Weekly Injection: How Next-Gen Half-Life Extension is Revolutionizing Biopharma in 2026
The biopharmaceutical landscape in 2026 is defined by one word: persistence. As the global market for GLP-1 agonists and Antibody-Drug Conjugates (ADCs) continues to shatter records, the industry's focus has shifted from "discovery" to "optimization." Patient adherence is no longer just a clinical goal—it is a market necessity. This is where the science of half-life extension...
0 Comments 0 Shares 52 Views 0 Reviews